FDA Approves New Oral Treatments for Gonorrhea
New Oral Treatments Offer Hope in Fight Against Rising Gonorrhea Rates
December 12, 2025 – In a significant step forward for public health, the U.S. Food and Drug Administration (FDA) has approved two new oral medications – Nuzolvence (zoliflodacin) and Blujepa (gepotidacin) – to treat uncomplicated urogenital gonorrhea. The approvals come at a critical time, as rates of this common sexually transmitted infection (STI) continue to climb globally, and antibiotic resistance poses an increasing threat.
A Growing Public Health Concern
Gonorrhea, caused by the bacterium Neisseria gonorrhoeae, is a major public health challenge. According to the Centers for Disease Control and Prevention (CDC), over 1.6 million cases of gonorrhea were reported in the United States in 2022, a substantial increase from previous years. Globally, the World Health Organization (WHO) estimates that over 87 million people are infected with gonorrhea annually. Left untreated, gonorrhea can lead to serious complications, including pelvic inflammatory disease, infertility, and increased risk of HIV transmission.
For years, treatment relied on a combination of ceftriaxone, an injectable antibiotic, and azithromycin, an oral medication. However, increasing resistance to azithromycin has prompted a shift towards single-dose ceftriaxone injections. The emergence of resistance to ceftriaxone is a growing concern, making the development of new treatment options vital.
Nuzolvence and Blujepa: How They Work
Nuzolvence, a granule formulation that dissolves in water, is approved for adults and children 12 years and older weighing at least 77 pounds. Blujepa, an oral tablet, is indicated for the same condition in patients 12 years and older weighing at least 99 pounds, but is specifically intended for those with limited treatment options due to potential safety concerns. Blujepa previously received FDA approval in March 2025 for treating urinary tract infections.
“These approvals mark a significant milestone for treatment options for patients with uncomplicated urogenital gonorrhea,” stated Dr. Adam Sherwat, director of the Office of Infectious Diseases at the FDA’s Center for Drug Evaluation and Research (CDER). “The availability of additional treatment options is of particular importance given the global rise in gonococcal drug resistance,” added Dr. Peter Kim, director of the CDER Division of Anti-infectives.
Clinical Trial Results: Comparable Effectiveness
Clinical trials demonstrated that both new medications are comparable in effectiveness to the current standard of care. A study involving 930 patients showed that 91% of those treated with Nuzolvence were cured, compared to 96% of those receiving ceftriaxone plus azithromycin. Similarly, a trial with 628 patients found that 93% of individuals treated with Blujepa achieved bacterial clearance, versus 91% in the standard treatment group.
These results offer reassurance that the new oral treatments are a viable alternative, potentially improving patient convenience and adherence to therapy. The ease of oral administration could be particularly beneficial for individuals who may face barriers to accessing healthcare facilities for injections.
Safety Considerations and Side Effects
While both medications have shown promising results, it’s crucial to be aware of potential side effects. The most common side effects reported in the Nuzolvence trial included low white blood cell counts, headache, dizziness, nausea, and diarrhea. Animal studies have raised concerns about potential birth defects, pregnancy loss, and male fertility problems, necessitating careful consideration for patients who are pregnant or planning to conceive.
Blujepa’s clinical trial revealed common side effects such as diarrhea, nausea, stomach pain, vomiting, gas, dizziness, soft stools, headache, tiredness, and excessive sweating. The FDA has also issued warnings regarding potential effects on heart rhythm and brain chemicals, as well as the possibility of allergic reactions.
Looking Ahead: A Multi-Pronged Approach
The FDA granted both Nuzolvence and Blujepa Fast Track, Qualified Infectious Disease Product, and Priority Review designations, highlighting the urgent need for new gonorrhea treatments. These designations expedite the development and review process, bringing potentially life-changing medications to patients more quickly.
However, new treatments alone are not enough to combat the gonorrhea epidemic. A comprehensive approach is needed, including increased access to testing and treatment, public health education campaigns promoting safe sexual practices, and ongoing surveillance to monitor antibiotic resistance patterns. For more information on STIs and sexual health, visit worldys.news’s sexual health section.
The approvals of Nuzolvence and Blujepa represent a vital step in the ongoing battle against gonorrhea, offering renewed hope for effective treatment and control of this widespread infection. Continued research and a commitment to public health initiatives are essential to protect individuals and communities from the devastating consequences of this STI.